Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-102 in advanced solid tumors
NCT04735796Phase 1Terminated
- Sponsor
- LaNova Medicines
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tecotabart in solid tumor (5 arms), sponsored by LaNova Medicines. Primary endpoints: Number of participants with adverse events and serious adverse events up to 1 year, Maximum Tolerated Dose and 4 more. Started May 2021; status: terminated.
02
Drugs
tecotabart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04735796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735796.